Announcing Kevin Quann as Assistant Professor of Medicine

October 7, 2025

Please join us in congratulating Kevin Quann, MD, PhD, in his new role as Assistant Professor in the Department of Medicine, Division of Malignant Hematology and Medical Oncology at the University of Pittsburgh, effective September 1, 2025.

In his new role, Dr. Quann will develop an independently funded and nationally recognized research program in Cancer Immunology and Immunotherapy including collaborative efforts with both basic research and clinical faculty across UPMC Hillman Cancer Center.

Dr. Quann’s primary research focus has been on understanding the role of progenitor-like T cells as a source of pathological alloreactivity in graft-vs-host disease (GVHD). He is also interested in novel approaches for identifying unknown allo-antigens in hematopoietic stem cell transplantation, with the goal of developing engineered allografts that maximize therapeutic graft-vs-leukemia (GVL) effects, while avoiding GVHD.

He is an active member of the scientific community with nearly two dozen peer-reviewed publications and service as a reviewer for journals and scientific societies. He has delivered many presentations to the scientific community. His past institutions, and more recently, the American Society for Transplantation and Cellular Therapy have honored Dr. Quann for his research activities. His basic and translational research program is funded in part through an ASTCT New Investigator Award.

Dr. Quann is board certified in internal medicine, hematology and medical oncology. He earned a BS in biomedical engineering from Drexel University and his MD and a PhD in cell and developmental biology from the Sidney Kimmel Medical College of Thomas Jefferson University. He has been in Pittsburgh since 2016 as he completed his internal medicine residency, hematology/ medical oncology fellowship, and post-doctoral training at UPMC. In August 2023, he became Instructor of Medicine.